
This retrospective study of 303 CBF and NPM1-mutated AML patients (aged 18-60) highlights the benefit of molecular monitoring and preemptive therapy over salvage therapy after morphologic relapse. Preemptive treatment significantly improved overall survival, suggesting its consideration in patient management.
Like
Save
Share